News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ranbaxy Laboratories (RANBAXY.BO) In Tie-Up For Generic Of Novartis AG (NVS)'s Diovan, If Approved, Ranbaxy Could Grab 50 Percent Of Its $1.5 Billion Market


1/17/2014 7:25:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Drug maker Ranbaxy Laboratories is learnt to have partnered another multinational pharmaceuticals company for sourcing active pharmaceutical ingredients, or API, for the generic version of anti-hypertension drug Diovan. Sources said the company had already filed an application with the US regulator, seeking permission for the partnership. A detailed email questionnaire sent to Ranbaxy on Monday did not elicit any response.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES